Semaglutide vs. liraglutide: three head-to-head trials, one pattern

Liraglutide came first, with its initial US approval in 2010. Its labels describe a GLP-1 analogue with 97% sequence homology to the human hormone and a C-16 fatty acid attached so it binds albumin, which gives an elimination half-life of about 13 hours and a daily injection. Semaglutide, first approved in 2017, keeps 94% homology but adds a C-18 fatty di-acid on a spacer and a change at position 8 that blocks breakdown by the DPP-4 enzyme; its half-life is about one week. The brand map follows from that. Liraglutide is Victoza, up to 1.8 mg daily for type 2 diabetes from age 10, and Saxenda, 3 mg daily for weight management, which Novo Nordisk is discontinuing. Semaglutide is Ozempic, up to 2 mg weekly for type 2 diabetes; Wegovy, 2.4 mg or 7.2 mg weekly or a 25 mg daily tablet for weight; and Rybelsus, oral tablets for type 2 diabetes.

Three randomized trials put the molecules against each other, and each tested a different pairing. STEP 8 (JAMA, 2022) enrolled 338 adults with overweight or obesity and no diabetes for 68 weeks: semaglutide 2.4 mg weekly reduced weight by 15.8%, liraglutide 3.0 mg daily by 6.4%, and pooled placebo by 1.9%. SUSTAIN 10 (Diabetes & Metabolism, 2020) enrolled 577 adults with type 2 diabetes on one to three oral drugs for 30 weeks: from a baseline HbA1c of 8.2%, semaglutide 1.0 mg weekly lowered it by 1.7 points against 1.0 for liraglutide 1.2 mg daily, and weight fell 5.8 kg against 1.9 kg. PIONEER 4 (The Lancet, 2019) matched oral semaglutide 14 mg daily with injected liraglutide 1.8 mg daily in 711 adults with type 2 diabetes: at 26 weeks HbA1c fell 1.2 against 1.1 points, which met non-inferiority, while weight fell 4.4 kg against 3.1 kg. The pattern holds across all three: semaglutide never did worse, the gap was widest for weight, and the margin narrowed when semaglutide was given by mouth rather than by injection.

Both molecules share a gastrointestinal profile of nausea, diarrhea, vomiting and reduced appetite, and both labels carry the rodent thyroid C-cell tumor boxed warning with the MTC and MEN 2 contraindication. Where the two separate, the trials disagree about which is easier to stay on. In SUSTAIN 10, gastrointestinal disorders affected 43.9% on semaglutide and 38.3% on liraglutide, and 11.4% stopped semaglutide early for adverse events against 6.6% for liraglutide. In STEP 8, at higher weight-management doses, the dropout pattern reversed: 12.6% stopped liraglutide for adverse events against 3.2% for semaglutide. PIONEER 4 reported adverse events in 80% on oral semaglutide and 74% on liraglutide. The Victoza label lists nausea in 20% at 1.8 mg against 5% on placebo. Both labels also warn of low blood sugar when combined with insulin or a sulfonylurea, and of pancreatitis and gallbladder disease.

For most adults choosing today, semaglutide is the default the evidence points to: it matched or beat liraglutide in every head-to-head trial, needs one injection a week rather than seven, comes as a tablet too, and carries more label indications, including heart, kidney and liver claims across its brands. Liraglutide still has a place. Its 13-hour half-life means it leaves the body within days if a side effect appears, where semaglutide lingers for weeks, which can matter when a drug has to be stopped quickly. Victoza is approved for type 2 diabetes from age 10, while the Ozempic label has not established use in anyone under 18. And people who have been stable on liraglutide for years, with good control and few side effects, gain little from switching purely because a newer molecule exists. Weekly semaglutide costs $349 a month self-pay as Ozempic at 0.25 mg to 1 mg (NovoCare Ozempic price guide, May 2026 edition, checked 28 Sep 2026). Neither molecule suits someone with a personal or family history of medullary thyroid carcinoma or MEN 2, and switching between them is a prescriber decision, not a dose swap.